Tenofovir, Emtricitabine, Efavirenz and Atazanavir Pharmacokinetics in the Aging HIV-Infected Population
NCT ID: NCT01180075
Last Updated: 2014-12-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
85 participants
OBSERVATIONAL
2010-05-31
2014-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Participants: The population will comprise of 56 (6 for intensive PK and 50 for sparse sampling) HIV-infected adults currently adhering to an antiretroviral regimen containing efavirenz with tenofovir and emtricitabine and the same number and distribution of HIV-infected adults currently adhering to an antiretroviral regimen containing atazanavir boosted with ritonavir with tenofovir and emtricitabine.
Procedures (methods): This study will be completed at the University of North Carolina at Chapel Hill. There will be four groups of subjects: Efavirenz/tenofovir/emtricitabine Group A, Efavirenz/tenofovir/emtricitabine Group B, Atazanavir/ritonavir/tenofovir/emtricitabine Group A, and Atazanavir/ritonavir/tenofovir/emtricitabine Group B.
The initial six subjects (Group A) for intensive PK analysis for each regimen will be recruited from the the UNC ID Clinic or the Moses Cone Health System Infectious Diseases Clinic, and will be comprised of non-frail subjects not currently receiving interacting drugs. If subjects provide informed consent, timed blood samples will be obtained to determine pharmacokinetic parameters around an observed dose of one of the two study regimens. A whole blood sample will also be collected and stored for potential drug metabolizing enzymes and transporters genotyping in the future. Group A subjects will complete a follow-up visit after their sampling visit.
50 subsequent subjects (Group B) for each regimen will be screened simultaneously, with no more than 10 subjects enrolled for each regimen in Group B prior to the completion and analysis of Group A. These subjects will also be recruited from either site. Group B subjects will have one or two sampling visits with 1 to 4 blood samples obtained at each visit, with a stored sample for future genotyping obtained on one of the visits. Samples will be collected just prior to a dose, at 2 hours, between 4 and 6 hrs, and between 10 and 14 hours after a medication dose. These visits may coincide with the subjects' regularly scheduled visit to the clinic, or be scheduled separately, depending on the preference and availability of the subject.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
TDF/FTC/EFV Intensive Sampling-Group A
Patients receiving TDF/FTC/EFV who undergo intensive pharmacokinetic sampling over 24 hours
tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Patients receiving this drug for clinical care at standard dosages will be enrolled.
Phlebotomy
Multiple blood draws will be performed in the study, and vary depending on the group.
TDF/FTC/ATV/r Intensive Sampling Group A
Patients receiving TDF/FTC/ATV/r who undergo intensive pharmacokinetic sampling over 24 hours
tenofovir/emtricitabine (TDF/FTC)
Patients receiving this drug for clinical care at standard dosages will be enrolled.
Atazanavir (ATV)
Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
Ritonavir
Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
Phlebotomy
Multiple blood draws will be performed in the study, and vary depending on the group.
TDF/FTC/EFV Sparse Sampling Group B
Patients receiving TDF/FTC/EFV who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Patients receiving this drug for clinical care at standard dosages will be enrolled.
Phlebotomy
Multiple blood draws will be performed in the study, and vary depending on the group.
TDF/FTC/ATV/r Sparse Sampling Group B
Patients receiving TDF/FTC/ATV/r who undergo sparse pharmacokinetic sampling on 1 or 2 visits depending on subject's availability
tenofovir/emtricitabine (TDF/FTC)
Patients receiving this drug for clinical care at standard dosages will be enrolled.
Atazanavir (ATV)
Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
Ritonavir
Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
Phlebotomy
Multiple blood draws will be performed in the study, and vary depending on the group.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)
Patients receiving this drug for clinical care at standard dosages will be enrolled.
tenofovir/emtricitabine (TDF/FTC)
Patients receiving this drug for clinical care at standard dosages will be enrolled.
Atazanavir (ATV)
Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
Ritonavir
Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
Phlebotomy
Multiple blood draws will be performed in the study, and vary depending on the group.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able to provide written informed consent
* Able to comply with their treatment regimen and study procedures
* Currently receiving either efavirenz/tenofovir/emtricitabine or atazanavir/ritonavir/tenofovir/emtricitabine as treatment for their HIV infection. Subjects must have been on the regimen for at least 2 weeks
* All women of reproductive potential must have a negative urine pregnancy test
* If participating in sexual activity that could lead to pregnancy, study participant must use at least one reliable method of contraception.
Exclusion Criteria
* Receiving an interacting medication
* Having missed \>3 doses of study medication in the past 30 days
* Patients who will not likely remain on the study regimen during the course of study participation.
* Anemia (hemoglobin \<10 g/dL)
* Abnormal screening laboratory findings
* Pregnancy
* Breastfeeding
* Any condition that may interfere with follow-up or the ability to take the study medication appropriately.
* Any clinically significant surgical alterations of the alimentary track, that in the opinion of the investigators, alters the absorption pharmacokinetics of the drugs of interest.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
University of North Carolina, Chapel Hill
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Julie Dumond, PharmD
Assistant Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Julie B Dumond, PharmD
Role: PRINCIPAL_INVESTIGATOR
University of North Carolina, Chapel Hill
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Dumond JB, Francis O, Cottrell M, Trezza C, Prince HM, Mollan K, Sykes C, Torrice C, White N, Malone S, Wang R, Van Dam C, Patterson KB, Hudgens MG, Sharpless NE, Forrest A. Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy. Antivir Ther. 2016;21(5):441-5. doi: 10.3851/IMP3017. Epub 2016 Jan 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-2120
Identifier Type: -
Identifier Source: org_study_id